Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application

加药 机制(生物学) 副作用(计算机科学) 医学 抗精神病药 临床疗效 药理学 重症监护医学 精神科 精神分裂症(面向对象编程) 内科学 计算机科学 认识论 哲学 程序设计语言
作者
Stefan Leucht,Josef Priller,John M. Davis
出处
期刊:American Journal of Psychiatry [American Psychiatric Association]
卷期号:181 (10): 865-878 被引量:28
标识
DOI:10.1176/appi.ajp.20240738
摘要

The introduction of the first antipsychotic drug, chlorpromazine, was a milestone for psychiatry. The authors review the history, classification, indications, mechanism, efficacy, side effects, dosing, drug initiation, switching, and other practical issues and questions related to antipsychotics. Classifications such as first-generation/typical versus second-generation/atypical antipsychotics are neither valid nor useful; these agents should be described according to the Neuroscience-based Nomenclature (NbN). Antipsychotic drugs are not specific for treating schizophrenia. They reduce psychosis regardless of the underlying diagnosis, and they go beyond nonspecific sedation. All currently available antipsychotic drugs are dopamine blockers or dopamine partial agonists. In schizophrenia, effect sizes for relapse prevention are larger than for acute treatment. A major unresolved problem is the implausible increase in placebo response in antipsychotic drug trials over the decades. Differences in side effects, which can be objectively measured, such as weight gain, are less equivocal than differences in rating-scale-measured (subjective) efficacy. The criteria for choosing among antipsychotics are mainly pragmatic and include factors such as available formulations, metabolism, half-life, efficacy, and side effects in previous illness episodes. Plasma levels help to detect nonadherence, and once-daily dosing at night (which is possible with many antipsychotics) and long-acting injectable formulations are useful when adherence is a problem. Dose-response curves for both acute treatment and relapse prevention follow a hyperbolic pattern, with maximally efficacious average dosages for schizophrenia of around 5 mg/day risperidone equivalents. Computer apps facilitating the choice between drugs are available. Future drug development should include pharmacogenetics and focus on drugs for specific aspects of psychosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爆米花应助ynx采纳,获得10
1秒前
2秒前
Summer完成签到,获得积分10
2秒前
slx完成签到,获得积分10
3秒前
桃子发布了新的文献求助10
4秒前
酷波er应助xxy采纳,获得10
4秒前
5秒前
Chen完成签到 ,获得积分10
5秒前
幽默果汁完成签到 ,获得积分10
5秒前
艾妮吗完成签到,获得积分10
5秒前
思源应助乘风采纳,获得10
6秒前
我是老大应助天蓝采纳,获得10
6秒前
英俊的铭应助欣慰的鹭洋采纳,获得10
6秒前
7秒前
ynx给ynx的求助进行了留言
7秒前
夏12完成签到,获得积分10
7秒前
汉堡包应助蔡宇滔采纳,获得10
8秒前
领导范儿应助甘乐采纳,获得10
8秒前
朴素的羊发布了新的文献求助10
8秒前
9秒前
10秒前
小王的求学日记本完成签到,获得积分10
10秒前
11秒前
希望天下0贩的0应助ALiyyyn采纳,获得10
12秒前
13秒前
蔡宇滔发布了新的文献求助10
13秒前
13秒前
14秒前
HsK发布了新的文献求助10
14秒前
大模型应助我要发sci采纳,获得10
15秒前
情怀应助朴素的羊采纳,获得10
15秒前
16秒前
吴彦祖发布了新的文献求助10
17秒前
zyt完成签到,获得积分10
17秒前
17秒前
彭于晏应助桃子采纳,获得10
17秒前
LI完成签到,获得积分20
17秒前
18秒前
沈清酌发布了新的文献求助10
18秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Reducing Compassion Fatigue, Secondary Traumatic Stress and Burnout 600
Comparative Elite Sport Development Systems, Structures and Public Policy 600
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Auslegungsgeschichte 500
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 500
What is the Future of Psychotherapy in Digital Age? Technology, AI Bots, and Psychotherapy after Covid 444
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7636827
求助须知:如何正确求助?哪些是违规求助? 9210630
关于积分的说明 19756417
捐赠科研通 7204369
什么是DOI,文献DOI怎么找? 3275551
关于科研通互助平台的介绍 2437291
邀请新用户注册赠送积分活动 2272685